D
Journey Medical Corporation
DERM
$5.31
$0.061.14%
D
Sell
11/19/2024Downgrade
Journey Medical Corporation (DERM) was downgraded to D- from D+ on 11/19/2024 due to a significant decline in the efficiency index, growth index and solvency index. Total capital declined 6.18% from $34.1M to $32M, total revenue declined 1.52% from $14.86M to $14.63M, and the quick ratio declined from 1.01 to 0.99.
Journey Medical Corporation (DERM) was downgraded to D- from D+ on 11/19/2024 due to a significant decline in the efficiency index, growth index and solvency index. Total capital declined 6.18% from $34.1M to $32M, total revenue declined 1.52% from $14.86M to $14.63M, and the quick ratio declined from 1.01 to 0.99.
D
Sell
8/16/2024Upgraded
Journey Medical Corporation (DERM) was upgraded to D+ from E+ on 8/16/2024 due to a significant increase in the efficiency index, growth index and total return index. EBIT increased 70.99% from -$10.09M to -$2.93M, earnings per share increased from -$0.5285 to -$0.1681, and net income increased 67.81% from -$10.44M to -$3.36M.
Journey Medical Corporation (DERM) was upgraded to D+ from E+ on 8/16/2024 due to a significant increase in the efficiency index, growth index and total return index. EBIT increased 70.99% from -$10.09M to -$2.93M, earnings per share increased from -$0.5285 to -$0.1681, and net income increased 67.81% from -$10.44M to -$3.36M.
E
Sell
5/30/2024Downgrade
Journey Medical Corporation (DERM) was downgraded to E+ from D- on 5/30/2024 due to a significant decline in the growth index, solvency index and volatility index. EBIT declined 379.56% from -$2.1M to -$10.09M, earnings per share declined from -$0.1191 to -$0.5285, and debt to equity increased from 0.87 to 1.37.
Journey Medical Corporation (DERM) was downgraded to E+ from D- on 5/30/2024 due to a significant decline in the growth index, solvency index and volatility index. EBIT declined 379.56% from -$2.1M to -$10.09M, earnings per share declined from -$0.1191 to -$0.5285, and debt to equity increased from 0.87 to 1.37.
D
Sell
1/11/2024Upgraded
Journey Medical Corporation (DERM) was upgraded to D- from E+ on 1/11/2024 due to an increase in the total return index and volatility index.
Journey Medical Corporation (DERM) was upgraded to D- from E+ on 1/11/2024 due to an increase in the total return index and volatility index.
E
Sell
12/4/2023Downgrade
Journey Medical Corporation (DERM) was downgraded to E+ from D- on 12/4/2023 due to a decline in the valuation index.
Journey Medical Corporation (DERM) was downgraded to E+ from D- on 12/4/2023 due to a decline in the valuation index.
D
Sell
11/16/2023Upgraded
Journey Medical Corporation (DERM) was upgraded to D- from E+ on 11/16/2023 due to a significant increase in the growth index, total return index and volatility index. EBIT increased 482.37% from -$4.51M to $17.25M, operating cash flow increased 372.34% from $3.97M to $18.75M, and earnings per share increased from -$0.4645 to $0.8.
Journey Medical Corporation (DERM) was upgraded to D- from E+ on 11/16/2023 due to a significant increase in the growth index, total return index and volatility index. EBIT increased 482.37% from -$4.51M to $17.25M, operating cash flow increased 372.34% from $3.97M to $18.75M, and earnings per share increased from -$0.4645 to $0.8.
E
Sell
3/14/2023Downgrade
Journey Medical Corporation (DERM) was downgraded to E+ from D- on 03/14/2023.
Journey Medical Corporation (DERM) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Journey Medical Corporation (DERM) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
Journey Medical Corporation (DERM) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Journey Medical Corporation (DERM) was downgraded to E+ from D- on 2/8/2023 due to a noticeable decline in the efficiency index, volatility index and solvency index. Debt to equity increased from 0.61 to 0.97, net income declined 33.9% from -$7.53M to -$10.08M, and total capital declined 7.99% from $56.07M to $51.59M.
Journey Medical Corporation (DERM) was downgraded to E+ from D- on 2/8/2023 due to a noticeable decline in the efficiency index, volatility index and solvency index. Debt to equity increased from 0.61 to 0.97, net income declined 33.9% from -$7.53M to -$10.08M, and total capital declined 7.99% from $56.07M to $51.59M.
D
Sell
8/1/2022Upgraded
Journey Medical Corporation (DERM) was upgraded to D- from E on 8/1/2022 due to an increase in the efficiency index, solvency index and volatility index. Net income increased 93.66% from -$21.75M to -$1.38M, and total capital increased 22.48% from $51.09M to $62.57M.
Journey Medical Corporation (DERM) was upgraded to D- from E on 8/1/2022 due to an increase in the efficiency index, solvency index and volatility index. Net income increased 93.66% from -$21.75M to -$1.38M, and total capital increased 22.48% from $51.09M to $62.57M.
E
Sell
5/1/2022Upgraded
Journey Medical Corporation (DERM) was upgraded to E from E- on 5/1/2022 due to a significant increase in the solvency index and valuation index. The quick ratio increased from 0.89 to 1.4.
Journey Medical Corporation (DERM) was upgraded to E from E- on 5/1/2022 due to a significant increase in the solvency index and valuation index. The quick ratio increased from 0.89 to 1.4.
E
Sell
2/8/2022None
Journey Medical Corporation (DERM) was downgraded to E- from U on 02/08/2022.
Journey Medical Corporation (DERM) was downgraded to E- from U on 02/08/2022.
NASDAQ
03/17/2025 4:00PM Eastern
Quotes delayed
